Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04855526 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

THC + CBD and Memory Study

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jun 30, 2022 to Dec 30, 2026
    • Start date: Apr 1, 2022 to Dec 1, 2025
    v4
  2. Start date: Nov 1, 2021 to Apr 1, 2022v3
  3. Start date: May 1, 2021 to Nov 1, 2021
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description expanded, about 3 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.
Trial Details
NCT Number NCT04855526
Lead Sponsor Hartford Hospital
Collaborators: Yale University
Conditions
(from sponsor)		 Marijuana Use, Cannabis Use, Cannabis Intoxication
Related terms Marijuana Abuse, Marijuana Use
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov